Prescient Therapeutics

Prescient Therapeutics R&D per Employee

The R&D Spending per Employee of Prescient Therapeutics (PTX.AX) as of Nov 22, 2026 is 1.76 M AUD. In the previous year, R&D Spending per Employee was 2.24 M AUD — a change of -21.37% (lower).

R&D per Employee

1.76 MAUD

YoY

-21.37%

Last updated:

R&D Spending per Employee of Prescient Therapeutics is 2026 1.76 M AUD. R&D Spending per Employee of Prescient Therapeutics was 2025 2.24 M AUD. It decreases by -21.37% lower compared to the previous year.

The Prescient Therapeutics R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
1.23 M AUD
Jan 1, 2020
920,000.00 AUD
Jan 1, 2021
831,666.67 AUD
Jan 1, 2022
1.13 M AUD
Jan 1, 2023
2.07 M AUD
Jan 1, 2024
2.32 M AUD
Jan 1, 2025
2.24 M AUD
Jan 1, 2026
1.76 M AUD
The Prescient Therapeutics R&D per Employee history
YEARR&D per EmployeeYoY
1.76 MAUD-21.37%
2.24 MAUD-3.68%
2.32 MAUD+12.07%
2.07 MAUD+83.00%
1.13 MAUD+36.27%
831,666.67AUD-9.60%
920,000.00AUD-25.05%
1.23 MAUD+79.01%
685,666.67AUD-15.43%
810,722.00AUD+204.83%
265,963.00AUD-19.11%
328,781.33AUD0.00%
328,781.33AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prescient Therapeutics Stock analysis

What does Prescient Therapeutics do? Prescient Therapeutics Ltd is an Australian biotechnology company focused on developing novel cancer therapies. The company was founded in 2006. Its business model is based on leveraging modern technologies and research findings to develop innovative solutions for cancer treatment. Prescient Therapeutics operates in two segments: drug development and research services. The company collaborates closely with leading scientists and medical institutions to utilize the latest advancements in cancer research and bring new drugs to the market. One of its products, PTX-200, is a novel inhibitor of protein kinase CK2 that has shown efficacy in clinical studies against various types of cancer. Another important product is OmniCAR, a next-generation CAR-T cell therapy that allows for selective recognition and destruction of cancer cells. Prescient Therapeutics aims to solidify its position as a leading provider of innovative cancer treatments through a rigorous validation strategy and collaboration with doctors and patients. The company has made significant progress in the development of new cancer therapies, holding numerous patents and establishing partnerships with leading medical institutions. Its goal is to meet the unmet needs of cancer patients and create a better future for cancer therapy. Prescient Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prescient Therapeutics stock

R&D Spending per Employee of Prescient Therapeutics is 1.76 M AUD in 2026.

R&D Spending per Employee of Prescient Therapeutics changed from 2.24 M AUD to 1.76 M AUD, representing a -21.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Prescient Therapeutics since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Prescient Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Prescient Therapeutics

All Key Metrics — Prescient Therapeutics